The importance of CXCR2 in pathological PMN recruitment to inflamed lungs is underlined by the extensive efforts put into development of CXCR2 antagonists as a therapeutic approach to prevent lung injury by neutrophils in, e.g., COPD and CF (22, 23). Here, CXCR2 is linked to chronic obstructive pulmonary disease.